AbbVie Inc., US00287Y1091

AbbVie stock after-hours at EUR 232.75: minus 0.47 percent versus prior close

Published on 09/29/2026 at 20:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie stock was at EUR 232.75 after-hours at 8:41 p.m. CEST on September 29, 2026, down 0.47 percent versus the prior close at Lang & Schwarz. AbbVie also announced an AI partnership.

Fotorealistisches Pharma-Forschungslabor mit Petrischalen und Wissenschaftlern in Schutzkleidung
AbbVie Inc. US00287Y1091 fotorealistisches Pharma Forschungslabor mit Petrischalen Wissenschaftlern Immunologie Onkologie Biopharma, Illustration mit AI erstellt.

AbbVie Inc. was at EUR 232.75 after-hours at 8:41 p.m. CEST on September 29, 2026, down 0.47 percent versus the prior close of EUR 233.85 at Lang & Schwarz.

AbbVie expands clinical-development AI work

AbbVie announced on September 29 that it is partnering with Valkai, a life sciences artificial-intelligence platform, to strengthen AI capabilities across clinical development. According to the AbbVie release, the partnership will deploy purpose-built AI capabilities across targeted areas of clinical research to improve efficiency and generate insights more quickly.

FDA approves JUVMO for Parkinson’s disease

In a separate announcement dated September 28, AbbVie said the U.S. Food and Drug Administration approved JUVMO, or tavapadon, for the treatment of adults with Parkinson’s disease. The company release said JUVMO is a selective D1/D5 receptor agonist and that AbbVie expects to make it available to U.S. patients in October 2026.

Disclaimer...

en | US00287Y1091 | ABBVIE INC. | boerse | 70200454 | bgmi